On June 18, BeiGene rose 3.05% in regular trading, trading at 162.5 HKD/share, with turnover of HKD 146 million.

On the news front, BeiGene recently announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Tevimbra (tislelizumab) targeting esophageal squamous cell carcinoma, marking a key milestone in the company's overseas indication expansion for its core PD-1 product. Additionally, the company's Q1 net profit attributable to shareholders surged 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.

The broader biotechnology sector rallied in tandem today, with AKESO up 5.48%, SKB BIO up 3.52%, 3SBIO up 2.55%, INNOVENT BIO up 2.54%, and REMEGEN up 2.52%, providing sector-wide support to BeiGene as a heavyweight constituent.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)